Immunogenicity of the BA.1 and BA.4/BA.5 Severe Acute Respiratory Syndrome Coronavirus 2 Bivalent Boosts: Preliminary Results From the COVAIL Randomized Clinical Trial

Authors

• Angela R. Branche, Department of Medicine, University of Rochester VTEU, Rochester, New York, USA.
• Nadine G. Rouphael, Department of Medicine, Emory University Hope Clinic, Decatur, Georgia, USA.
• Cecilia Losada, Department of Medicine, Emory University Hope Clinic, Decatur, Georgia, USA.
• Lindsey R. Baden, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
• Evan J. Anderson, Center for Childhood Infections and Vaccines (CCIV) of Children's Healthcare of Atlanta and Emory University Department of Pediatrics, Atlanta, Georgia, USA.
• Anne F. Luetkemeyer, Zuckerberg San Francisco General, University of California San Francisco, San Francisco, California, USA.
• David J. Diemert, George Washington Vaccine Research Unit, George Washington University, Washington DC, USA.
• Patricia L. Winokur, Department of Medicine, University of Iowa College of Medicine, Iowa City, Iowa, USA.
• Rachel M. Presti, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
• Angelica C. Kottkamp, Department of Medicine, New York University (NYU) Vaccine and Treatment Evaluation Unit (VTEU) Manhattan Research Clinic at NYU Grossman School of Medicine, New York, New York, USA.
• Ann R. Falsey, Department of Medicine, University of Rochester VTEU, Rochester, New York, USA.
• Sharon E. Frey, Saint Louis University, Center for Vaccine Development, St. Louis, Missouri, USA.
• Richard Rupp, Department of Pediatrics, University of Texas Medical Branch, Galveston, Texas, USA.
• Martín Bäcker, Department of Medicine, NYU VTEU Long Island Research Clinic at NYU Long Island School of Medicine, Mineola, New York, USA.
• Richard M. Novak, Department of Medicine, University of Illinois at Chicago-Project WISH, Chicago, Illinois, USA.
• Emmanuel B. Walter, Department of Pediatrics, Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, USA.
• Lisa A. Jackson, Kaiser Permanente Washington Health Research Institute, Seattle, Washington, USA.
• Susan J. Little, Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California San Diego, La Jolla, California, USA.
• Lilly C. Immergluck, Department of Microbiology/Biochemistry/Immunology, Morehouse School of Medicine, Atlanta, Georgia, USA.
• Siham M. Mahgoub, Department of Medicine, Howard University College of Medicine, Howard University Hospital, Washington DC, USA.
• Jennifer A. Whitaker, Departments of Molecular Virology and Microbiology and Medicine, Baylor College of Medicine, Houston, Texas, USA.
• Tara M. Babu, Departments of Medicine, Epidemiology, and Laboratory Medicine & Pathology, University of Washington, Vaccines and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
• Paul A. Goepfert, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
• Dahlene N. Fusco, Department of Medicine, Tulane University School of Medicine, New Orleans, Louisiana, USA.
• Robert L. Atmar, Departments of Molecular Virology and Microbiology and Medicine, Baylor College of Medicine, Houston, Texas, USA.
• Christine M. Posavad, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center and Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.
• Antonia Netzl, Centre for Pathogen Evolution, Department of Zoology, University of Cambridge, Cambridge, United Kingdom.
• Derek J. Smith, Centre for Pathogen Evolution, Department of Zoology, University of Cambridge, Cambridge, United Kingdom.
• Kalyani Telu, The Emmes Company, LLC, Rockville, Maryland, USA.
• Jinjian Mu, The Emmes Company, LLC, Rockville, Maryland, USA.
• Mat Makowski, The Emmes Company, LLC, Rockville, Maryland, USA.
• Mamodikoe K. Makhene, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.

Document Type

Journal Article

Publication Date

8-22-2023

Journal

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Volume

77

Issue

4

DOI

10.1093/cid/ciad209

Keywords

SARS-CoV-2; vaccine; variant

Abstract

In a randomized clinical trial, we compare early neutralizing antibody responses after boosting with bivalent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger RNA (mRNA) vaccines based on either BA.1 or BA.4/BA.5 Omicron spike protein combined with wild-type spike. Responses against SARS-CoV-2 variants exhibited the greatest reduction in titers against currently circulating Omicron subvariants for both bivalent vaccines.

APA Citation

Branche, Angela R.; Rouphael, Nadine G.; Losada, Cecilia; Baden, Lindsey R.; Anderson, Evan J.; Luetkemeyer, Anne F.; Diemert, David J.; Winokur, Patricia L.; Presti, Rachel M.; Kottkamp, Angelica C.; Falsey, Ann R.; Frey, Sharon E.; Rupp, Richard; Bäcker, Martín; Novak, Richard M.; Walter, Emmanuel B.; Jackson, Lisa A.; Little, Susan J.; Immergluck, Lilly C.; Mahgoub, Siham M.; Whitaker, Jennifer A.; Babu, Tara M.; Goepfert, Paul A.; Fusco, Dahlene N.; Atmar, Robert L.; Posavad, Christine M.; Netzl, Antonia; Smith, Derek J.; Telu, Kalyani; Mu, Jinjian; Makowski, Mat; and Makhene, Mamodikoe K., "Immunogenicity of the BA.1 and BA.4/BA.5 Severe Acute Respiratory Syndrome Coronavirus 2 Bivalent Boosts: Preliminary Results From the COVAIL Randomized Clinical Trial" (2023). GW Authored Works. Paper 3218.
https://hsrc.himmelfarb.gwu.edu/gwhpubs/3218

Department

Medicine